Home LiteratureArticle Details
PMID: 10623795 Published · ppublish English Journal Article

Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen.

Journal of immunology (Baltimore, Md. : 1950) ·Vol. 164 ·No. 2 ·2000-01-15 ·Pages 562-5

Surman DR, Dudley ME, Overwijk WW, Restifo NP

Abstract

Neoantigens resulting from the inherent genomic instability of tumor cells generally do not trigger immune recognition. Similarly, transfection of tumors with model Ags often fails to elicit CD8+ T cell responses or alter a tumor's growth rate or lethality. We report here that the adoptive transfer of activated Th1-type CD4+ T cells specific for a model tumor Ag results in the de novo generation of CD8+ T cells with specificity to that Ag and concomitant tumor destruction. The anti-tumor effects of the CD4+ T cells required the presence of both MHC class I and class II on host cells, as evidenced by experiments in knockout mice, suggesting that CD4+ T cells enhanced the ability of host APC to activate endogenous CD8+ T cells. These results indicate that the apparent inability of tumor cells expressing highly immunogenic epitopes to activate tumor-specific CD8+ T cells can be altered by activated CD4+ T cells.

MeSH Terms
Adoptive Transfer Animals Antigens, Neoplasm/immunology CD4-Positive T-Lymphocytes/immunology CD8-Positive T-Lymphocytes/immunology Cell Movement/immunology Clone Cells/immunology,transplantation Epitopes, T-Lymphocyte/immunology Histocompatibility Antigens Class I/physiology Histocompatibility Antigens Class II/physiology Lymphocyte Activation/immunology Mice Mice, Inbred C57BL Models, Immunological Neoplasm Transplantation Sarcoma, Experimental/enzymology,immunology,therapy Tumor Cells, Cultured beta-Galactosidase/biosynthesis,immunology
Chemicals
Antigens, Neoplasm Epitopes, T-Lymphocyte Histocompatibility Antigens Class I Histocompatibility Antigens Class II beta-Galactosidase
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Surman D R
Surgery Branch, National Cancer Institute, Bethesda, MD 20892, USA.
Dudley M E
Overwijk W W
Restifo N P
References (26)
26 references, click to expand
  1. CD4+ T cell help impairs CD8+ T cell deletion induced by cross-presentation of self-antigens and favors autoimmunity.
    J Exp Med. 1997 Dec 15;186(12):2057-62 PMID: 9396776
  2. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors.
    J Exp Med. 1998 Mar 2;187(5):693-702 PMID: 9480979
  3. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell.
    Nature. 1998 Jun 4;393(6684):474-8 PMID: 9624003
  4. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions.
    Nature. 1998 Jun 4;393(6684):480-3 PMID: 9624005
  5. T cell-mediated, IFN-gamma-facilitated rejection of murine B16 melanomas.
    J Immunol. 1998 Jul 15;161(2):897-908 PMID: 9670968
  6. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand.
    J Exp Med. 1998 Jul 20;188(2):277-86 PMID: 9670040
  7. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses.
    J Exp Med. 1998 Dec 21;188(12):2199-204 PMID: 9858506
  8. Viral immune evasion due to persistence of activated T cells without effector function.
    J Exp Med. 1998 Dec 21;188(12):2205-13 PMID: 9858507
  9. Genetic instabilities in human cancers.
    Nature. 1998 Dec 17;396(6712):643-9 PMID: 9872311
  10. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes.
    Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2982-7 PMID: 10077623
  11. Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells.
    J Exp Med. 1985 May 1;161(5):1122-34 PMID: 3921652
  12. Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. Evidence for paracrine immune effects of tumor necrosis factor against tumors.
    J Immunol. 1991 May 1;146(9):3227-34 PMID: 2016545
  13. CD4+ T cell clones specific for the human p97 melanoma-associated antigen can eradicate pulmonary metastases from a murine tumor expressing the p97 antigen.
    J Immunol. 1991 May 1;146(9):3235-41 PMID: 1707934
  14. Insertion signal sequence fused to minimal peptides elicits specific CD8+ T-cell responses and prolongs survival of thymoma-bearing mice.
    Cancer Res. 1994 Aug 1;54(15):4155-61 PMID: 7518351
  15. CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection.
    J Virol. 1994 Dec;68(12):8056-63 PMID: 7966595
  16. Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen.
    J Immunol. 1995 May 1;154(9):4685-92 PMID: 7722321
  17. T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes.
    Immunol Rev. 1995 Jun;145:167-77 PMID: 7590825
  18. Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo?
    J Exp Med. 1996 Mar 1;183(3):769-76 PMID: 8642281
  19. High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10.
    J Exp Med. 1996 Aug 1;184(2):741-6 PMID: 8760828
  20. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation.
    J Exp Med. 1996 Aug 1;184(2):747-52 PMID: 8760829
  21. The new vaccines: building viruses that elicit antitumor immunity.
    Curr Opin Immunol. 1996 Oct;8(5):658-63 PMID: 8902391
  22. Identification of a Kb-restricted CTL epitope of beta-galactosidase: potential use in development of immunization protocols for "self" antigens.
    Methods. 1997 Jun;12(2):117-23 PMID: 9184376
  23. Killing of rat adenocarcinoma 13762 in situ by adoptive transfer of CD4+ anti-tumor T cells requires tumor expression of cell surface MHC class II molecules.
    Cell Immunol. 1997 May 25;178(1):79-90 PMID: 9184701
  24. Self antigens expressed by solid tumors Do not efficiently stimulate naive or activated T cells: implications for immunotherapy.
    J Exp Med. 1997 Aug 29;186(5):645-53 PMID: 9271580
  25. Compact, synthetic, vaccinia virus early/late promoter for protein expression.
    Biotechniques. 1997 Dec;23(6):1094-7 PMID: 9421642
  26. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression.
    Proc Natl Acad Sci U S A. 1998 Feb 3;95(3):1178-83 PMID: 9448305
Article Info
Journal
Journal of immunology (Baltimore, Md. : 1950)
Abbr.
J Immunol
ISSN
0022-1767
Published
2000-01-15
Pages
562-5
Language
English
Region
United States
NLM ID
2985117R
PMCID
PMC2239008
Subset
IM
Grants
Intramural NIH HHS · Z01 BC010763-01 · United States
Intramural NIH HHS · Z99 CA999999 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com